Company profile
AVALO THERAPEUTICS, INC.
NASDAQ:AVTXBiotechnology: Pharmaceutical Preparations
Drug pipeline (4)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| QUISOVALIMAB | phase2 | — | 2 | completed, terminated |
| RISLENEMDAZ | phase2 | — | 2 | no active trials |
| CAMOTESKIMAB | phase1 | — | 2 | no active trials |
| OSI-027 | phase1 | — | 1 | withdrawn |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (10)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04994002 | phase1 | withdrawn | 2021-09-03 | 2022-06-01 | Avalo Therapeutics, Inc. | A Pharmacokinetic, Pharmacodynamic, Safety and Tolerability Study of CERC-006 in Adults With Complex Lymphatic Malformations |
| NCT01941043 | phase2 | completed | 2013-11-01 | 2014-09-01 | Avalo Therapeutics, Inc. | A Randomized, Double-Blind, Placebo-Controlled, Sequential Parallel Study of CERC-301 in the Adjunctive Treatment of Subjects With Severe Depression and Recent Active Suicidal Ideation Despite Antidepressant Treatment |
| NCT01579526 | phase1 | completed | 2012-04-01 | 2012-04-01 | Avalo Therapeutics, Inc. | A Single Dose Study to Determine the Safety and Pharmacokinetics of FP01 Lozenges in Healthy Volunteers |
| NCT02459236 | phase2 | completed | 2015-06-01 | 2016-09-01 | Avalo Therapeutics, Inc. | A Study of Intermittent Doses of CERC-301 in MDD |
| NCT06603077 | phase2 | completed | 2024-09-16 | 2026-02-23 | Avalo Therapeutics, Inc. | A Study to Evaluate the Efficacy and Safety of AVTX-009 in Patients With Moderate to Severe Hidradenitis Suppurativa |
FDA applications (0)
No records yet.